Literature DB >> 9551953

Differences between responses of naive and activated T cells to anergy induction.

R J Hayashi1, D Y Loh, O Kanagawa, F Wang.   

Abstract

T cell unresponsiveness to Ag stimulation can be induced by several means. The precise mechanism by which this process occurs remains poorly understood. Preincubating T cells with either EDCI-fixed APC or ionomycin is a proven means of inducing T cell anergy with reduced IL-2 production in response to Ag stimulation. Using T cells from mice expressing the TCR transgene DO11.10, which is specific for a peptide (323-339) derived from hen egg OVA, we demonstrate that naive cells obtained directly from the host are resistant to the anergy induction by either fixed APC or ionomycin. TCR transgenic mice also deficient in the recombination-activating gene-2 (RAG-2(-/-)), preventing the formation of T cells with endogenous TCRs, were immunized with OVA, and in vivo activated T cells with low expression of CD62 were isolated. These primed cells possess the same sensitivity to ionomycin-induced anergy as in vitro activated cell lines. This unresponsive state most profoundly affects Ag-induced IL-2 production, with IFN-gamma and IL-3 affected to a lesser degree and no effect observed on IL-4 production. Thus, T cells in vivo can be distinguished phenotypically by their susceptibility to anergic stimuli. Anergy so induced affects selected T cell functions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551953

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  A logical analysis of T cell activation and anergy.

Authors:  M Kaufman; F Andris; O Leo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 2.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 3.  The peripheral generation of CD4+ CD25+ regulatory T cells.

Authors:  Arne N Akbar; Leonie S Taams; Mike Salmon; Milica Vukmanovic-Stejic
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

4.  Induction of T-cell activation or anergy determined by the combination of intensity and duration of T-cell receptor stimulation, and sequential induction in an individual cell.

Authors:  Tomohiro Yamamoto; Makoto Hattori; Tadashi Yoshida
Journal:  Immunology       Date:  2007-03-22       Impact factor: 7.397

5.  Ovalbumin-induced plasma interleukin-4 levels are reduced in ceramide kinase-deficient DO11.10 RAG1-/- mice.

Authors:  Satoru Niwa; Nicole Urtz; Thomas Baumruker; Andreas Billich; Frédéric Bornancin
Journal:  Lipids Health Dis       Date:  2010-01-06       Impact factor: 3.876

6.  Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells.

Authors:  Leona Gabrysová; Kirsty S Nicolson; Heather B Streeter; Johan Verhagen; Catherine A Sabatos-Peyton; David J Morgan; David C Wraith
Journal:  J Exp Med       Date:  2009-07-27       Impact factor: 14.307

7.  Normalization of tumor microenvironment by neem leaf glycoprotein potentiates effector T cell functions and therapeutically intervenes in the growth of mouse sarcoma.

Authors:  Subhasis Barik; Saptak Banerjee; Atanu Mallick; Kuntal Kanti Goswami; Soumyabrata Roy; Anamika Bose; Rathindranath Baral
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

8.  Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells.

Authors:  Amy E Anderson; Bethan L Sayers; Muzlifah A Haniffa; David J Swan; Julie Diboll; Xiao-Nong Wang; John D Isaacs; Catharien M U Hilkens
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

9.  CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells.

Authors:  Cecilia Fernandez-Ponce; Margarita Dominguez-Villar; Enrique Aguado; Francisco Garcia-Cozar
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.